BSI-401
| CAS No. | 142404-10-2 | Cat. No. | BCP27642 |
| Name | BSI-401 | ||
| Synonyms | BSI401;BSI 401; | ||
| Formula | C9H4INO4 | M. Wt | 317.04 |
| Description | BSI-401 is a novel PARP-1 inhibitor with both oral bioavailability and strong antitumor potency. The IC50 of BSI-401 for all of the five pancreatic cancer cell lines was <15 μM. BSI-401 inhibits the growth of pancreatic cancer cells in vitro significantly. BSI-401 inhibits low-anchorage tumor cell colony formation. BSI-401 combined with oxaliplatin had potent synergistic antitumor activity (46 versus 132 days, P = 0.0063), and significantly (P = 0.0148) prevented acute oxaliplatin-induced neurotoxicity. | ||
| Pathways | Cell Cycle/DNA Damage Epigenetics | ||
| Targets | PARP | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.